サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541100

緑内障治療薬市場レポート：薬剤クラス別、適応症別、エンドユーザー別、地域別、2024～2032年

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 135 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
緑内障治療薬市場レポート：薬剤クラス別、適応症別、エンドユーザー別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の緑内障治療薬市場規模は2023年に79億米ドルに達しました。今後、IMARC Groupは、2024～2032年の間に5.6％の成長率（CAGR）を示し、2032年までに132億米ドルに達すると予測しています。世界の緑内障の有病率の増加、早期発見のための診断技術の継続的な進歩、眼科における遠隔医療の採用の増加、外科手術における数々の技術革新は、市場を推進している要因のいくつかを表しています。

緑内障治療薬市場分析

市場の成長と規模世界の緑内障治療薬市場は、世界の緑内障の有病率の増加や、この眼疾患に罹患しやすい高齢化人口の増加などの要因によって、緩やかな成長を遂げています。

主要市場促進要因：早期診断・治療薬の重要性に対する意識の高まりなどが挙げられます。

主要市場動向：緑内障管理に革命をもたらす可能性のある併用療法の採用や新規ドラッグデリバリーシステムの開発へのシフトが顕著です。こうした動向の背景には、より効果的な治療薬レジメンと患者のコンプライアンス向上へのニーズがあります。

地理的動向：北米は、高い医療費、確立された医療インフラ、緑内障に対する意識の高まりが市場を独占しています。しかし、アジア太平洋は、医療投資の増加と医療施設の改善により、急成長市場として浮上しています。

競合情勢：市場競争は緩やかで、複数の世界企業が市場を独占しています。これらの企業は、研究開発、戦略的提携、合併・買収（M&A）などを行い、市場での地位を固め、製品ポートフォリオを拡大しています。

課題と機会：課題には、厳しい規制の枠組み、高額な治療薬費、未発達地域における認知度の低さなどがあります。しかし、市場参入企業が革新的な製品を提供し差別化を図ることで、これらの課題を克服する機会が生まれると予測されます。

緑内障治療薬市場動向/促進要因

外科手術における数々の技術革新

外科手術における技術革新の出現は、世界市場に大きな影響を与えています。最も画期的な開発のひとつが低侵襲緑内障手術（MIGS）です。これらの外科的介入は、トラベクレクトミーのような伝統的な外科的方法よりも合併症が少なく、回復期間が短く、手術が容易であるため、変革的であることが証明されています。MIGSが容易に行えるようになったことで、外科医は患者の潜在的なリスクや不快感を最小限に抑えながら、病気を効果的に管理する選択肢が増えました。さらに、マイクロステントや新しいドレナージシステムなどの手術用医療機器の進歩は、緑内障手術の有効性をさらに向上させています。これらの進歩により、緑内障の実行可能な治療薬法としての外科的解決策に対する世界中の医療従事者や患者からの信頼が高まっています。

眼科における遠隔医療の採用増加

遠隔医療はますます医療に欠かせないものとなってきており、緑内障治療薬市場に関しては、眼科におけるその応用が特に注目されています。医療のデジタル化は、ソフトウェアやハードウェアの技術的進歩と相まって、遠隔診療を実用的かつ効果的なものにしました。患者は、頻繁に病院を訪れることなく自分の状態をモニターできるようになり、特に地方や遠隔地に住む人々にとって有益です。このように医療サービスが広く行き渡ることで、患者のエンゲージメントが高まり、転帰の改善に貢献します。遠隔診療は継続的なモニタリングを可能にし、リアルタイム・データは、即時の介入が必要な患者の状態の変化を医療プロバイダーに警告することができます。また、データ収集能力の向上は、これまでにない研究機会を提供し、新たな治療薬法の開発を加速させる可能性があります。

患者ケアへの全人的アプローチへの重点化

統合されたホリスティックな治療薬計画には、多くの場合、栄養士、理学療法士、心理カウンセラーなどを含む医療プロバイダーの多職種チームが関与します。これにより、患者により包括的な治療薬計画が提供されるだけでなく、医療エコシステム内でのクロスセリングやアップセリングの機会も広がります。焦点は症状の治療薬から、より統合的なアプローチへと移っており、医療的介入と並行して、患者教育、生活習慣の改善、予防措置を考慮に入れています。ホリスティックなアプローチでは、緑内障の管理における食事、運動、ストレス管理などのライフスタイル要因の役割も認識されます。患者には、緑内障の重要な要因である眼圧を下げるのに役立つ食べ物や活動タイプについての教育が行われます。このような多方面からのアプローチは、治療薬効果を高めるだけでなく、患者の生活の質を全体的に向上させる。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の緑内障治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • プロスタグランジン類似体
  • ベータ遮断薬
  • アルファアドレナリン作動薬
  • 炭酸脱水酵素阻害剤
  • 併用薬
  • その他

第7章 市場内訳：適応症別

  • 開放隅角緑内障
  • 閉塞隅角緑内障
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院
  • 眼科クリニック
  • 外来手術センター
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated（Bausch Health Companies Inc.）
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI S.p.A
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2023
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players
目次
Product Code: SR112024A2770

The global glaucoma therapeutics market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.6% during 2024-2032. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma Therapeutics Market Analysis:

Market Growth and Size: The global glaucoma therapeutics market is experiencing moderate growth, driven by factors like the increasing prevalence of glaucoma globally and a rising aging population susceptible to this eye condition.

Major Market Drivers: Key drivers include the growing awareness among individuals about the importance of early diagnosis and treatment.

Key Market Trends: There is a notable shift towards the adoption of combination therapies and the development of novel drug delivery systems, which are poised to revolutionize glaucoma management. These trends are driven by the need for more effective treatment regimens and improved patient compliance.

Geographical Trends: North America dominates the market, driven by high healthcare expenditure, a well-established healthcare infrastructure, and heightened awareness about glaucoma. However, Asia Pacific is emerging as a fast-growing market on account of the increasing healthcare investments and improving healthcare facilities.

Competitive Landscape: The market is moderately competitive, with several global players dominating the scene. These companies are engaged in research and development (R&D) activities, strategic alliances, and mergers and acquisitions (M&As) to consolidate their market positions and expand their product portfolios.

Challenges and Opportunities: Challenges include stringent regulatory frameworks, high treatment costs, and a lack of awareness in underdeveloped regions. Nonetheless, opportunities for market players to innovate and differentiate their offerings are projected to overcome these challenges.

Glaucoma Therapeutics Market Trends/Drivers:

Numerous technological innovation in surgical procedures

The advent of technological innovation in surgical procedures has significantly influenced the global market. One of the most groundbreaking developments is Minimally Invasive Glaucoma Surgeries (MIGS). These surgical interventions have proved to be transformative by causing fewer complications, necessitating shorter recovery periods, and being easier to perform than traditional surgical methods like trabeculectomy. The ease of MIGS has empowered surgeons with more options to manage the disease effectively while minimizing the potential risks and discomfort to the patient. In addition, advancements in surgical medical devices such as micro-stents and new drainage systems have further improved the effectiveness of glaucoma surgeries. These advancements have, in turn, increased the trust among healthcare practitioners and patients across the globe in surgical solutions as viable treatment options for glaucoma.

Rising adoption of telemedicine in ophthalmology

Telemedicine has increasingly become an integral part of healthcare, and its applications in ophthalmology are particularly noteworthy when it comes to the glaucoma therapeutics market. The digitalization of healthcare, coupled with technological advancements in software and hardware, has made remote consultations both practical and effective. Patients can now have their conditions monitored without the need for frequent hospital visits, which is especially beneficial for those residing in rural or remote locations. This wider reach of healthcare services enhances patient engagement, thereby contributing to better outcomes. Remote consultations enable continuous monitoring, and real-time data can alert healthcare providers to changes in a patient's condition that may require immediate intervention. The enhanced data collection capabilities also offer unprecedented opportunities for research, thereby potentially accelerating the development of new treatment modalities.

An enhanced focus on holistic approaches to patient care

An integrated, holistic treatment plan often involves a multi-disciplinary team of healthcare providers, including nutritionists, physiotherapists, and psychological counselors, among others. This not only gives patients a more comprehensive treatment plan but also opens up cross-selling and up-selling opportunities within the healthcare ecosystem. The focus has moved beyond treating the symptoms to a more integrated approach, taking into account patient education, lifestyle changes, and preventive measures alongside medical interventions. A holistic approach also recognizes the role of lifestyle factors such as diet, exercise, and stress management in managing glaucoma. Patients are educated about the types of foods and activities that can help in reducing intraocular pressure, which is a critical factor in glaucoma. This multi-pronged approach not only enhances the effectiveness of medical treatments but also improves the overall quality of life for the patients.

Glaucoma Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug class, indication and end user.

Breakup by Drug Class:

Prostaglandin Analogs

Beta Blockers

Alpha Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Combination Drugs

Others

Prostaglandin analogs represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes prostaglandin analogs, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and others. According to the report, prostaglandin analogs represented the largest segment.

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

Open Angle Glaucoma

Angle Closure Glaucoma

Others

Open angle glaucoma represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes open angle glaucoma, angle closure glaucoma and others. According to the report, open angle glaucoma represented the largest segment.

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving glaucoma therapeutics market demand. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

Hospitals

Ophthalmic Clinics

Ambulatory Surgery Centers

Others

Hospitals accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ophthalmic clinics, ambulatory surgery centers and others. According to the report, hospitals represented the largest segment.

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The glaucoma therapeutics market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel glaucoma therapeutics market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies, thereby offering a favorable glaucoma therapeutics market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Aerie Pharmaceuticals Inc.

Allergan Plc

Bausch & Lomb Incorporated (Bausch Health Companies Inc.)

Inotek Pharmaceuticals Corp.

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Santen Pharmaceutical Co. Ltd.

SIFI S.p.A

Teva Pharmaceutical Industries Ltd

Recent Developments:

In November 2022, Aerie Pharmaceuticals, Inc. was acquired by Alcon, the global leader in eye care. Through the transaction, Alcon has added the commercial products Rocklatan(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa(netarsudil ophthalmic solution) 0.02%, AR-15512, a Phase 3 product candidate for dry eye disease and also a pipeline of ophthalmic pharmaceutical product candidates.

In July 2023, Bausch Health Companies Inc. announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health.

Merck & Co. announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] >=1).

Key Questions Answered in This Report

  • 1. How big is the global glaucoma therapeutics market?
  • 2. What is the expected growth rate of the global glaucoma therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global glaucoma therapeutics market?
  • 4. What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5. What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6. What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7. What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8. What are the key regions in the global glaucoma therapeutics market?
  • 9. Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis